74-year-old male, AF and previous ablation of typical flutter, CHA2DS2-VASc, hematological high priority indication for Ibrutinib (high bleeding and pro-AF risk).
4 April 2022 (08:42 - 08:54)
Organised by:
Slides
About the speaker

University hospitals of Geneva, Geneva (Switzerland)
4 More presentations in this session

Professor M. Rienstra (Groningen, NL)

Doctor J. Saenen (Edegem, BE)
Access the full session
The Event
EHRA 2022
4 April 2022
08:42 CET




